![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/clarity-receives-fda-fast-track-designation-for-64cu-sar-bispsma-302228374.html
https://www.contractpharma.com/contents/view_breaking-news/2024-04-10/northstar-medical-radioisotopes-enters-clinical-supply-pact/?widget=listSection
https://www.prnewswire.com/news-releases/first-participant-treated-at-the-highest-dose-level-in-claritys-theranostic-prostate-cancer-trial-301909746.html
https://www.prnewswire.com/news-releases/clarity-establishes-a-us-center-of-excellence-for-targeted-copper-theranostics-301865488.html
https://www.prnewswire.com/news-releases/clarity-commences-combat-theranostic-prostate-cancer-trial-in-the-us-301855052.html
https://www.clinicaltrialsarena.com/news/clarity-completes-first-stage-of-prostate-cancer-trial/
https://www.prnewswire.com/news-releases/ind-approval-from-the-us-fda-for-theranostic-sar-bombesin-trial-in-prostate-cancer-301683510.html
https://www.clinicaltrialsarena.com/news/clarity-prostate-cancer-therapy-trial/
https://www.prnewswire.com/news-releases/first-patient-treated-in-claritys-therapeutic-prostate-cancer-trial-301643339.html